Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia

Pharmacogenomics Journal

Volumn 12, Issue 3, 2012, Pages 246-254

  Liu, W ^a   Downing, A C M ^a   Munsie, L M ^a   Chen, P ^a   Reed, M R ^a   Ruble, C L ^a   Landschulz, K T ^a   Kinon, B J ^a   Nisenbaum, L K ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

antipsychotics; HTR2A; metabotropic glutamate receptor agonist; NRG1; pharmacogenetics; schizophrenia

Indexed keywords

OLANZAPINE; PLACEBO; POMAGLUMETAD METHIONIL; SEROTONIN 2A RECEPTOR;

ADULT; ARTICLE; COHORT ANALYSIS; DRUG MECHANISM; DRUG RESPONSE; FEMALE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AMINO ACIDS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; EXCITATORY AMINO ACID AGONISTS; FEMALE; HAPLOTYPES; HUMANS; INTRONS; MALE; NEUREGULIN-1; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, METABOTROPIC GLUTAMATE; RUSSIA; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; UNITED STATES;

EID: 84861460686     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2010.90     Document Type: Article

References (38)

1. Rossler W, Salize HJ, van Os J, Riecher-Rossler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 2005; 15: 399-409. (Pubitemid 40943544)
2. Rogers DP, Goldsmith CA. Treatment of schizophrenia in the 21st Century: beyond the neurotransmitter hypothesis. Expert Rev Neurother 2009; 9: 47-54.
3. Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002; 63: 892-909. (Pubitemid 35231730)
4. Kane JM. Utilization of long-acting antipsychotic medication in patient care. CNS Spectr 2006; 11: 1-7.
5. Krystal JH, D'Souza DC, Petrakis IL, Belger A, Berman RM, Charney DS et al. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry 1999; 7: 125-143. (Pubitemid 30240826)
6. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001; 25: 455-467. (Pubitemid 32830950)
7. Mouri A, Noda Y, Enomoto T, Nabeshima T. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment. Neurochem Int 2007; 51: 173-184. (Pubitemid 47176714)
8. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007; 13: 1102-1107. (Pubitemid 47517511)
9. Arranz MJ, Kapur S. Pharmacogenetics in psychiatry: are we ready for widespread clinical use? Schizophr Bull 2008; 34: 1130-1144.
10. Patnaik M, Renda MJ, Athanasiou MC, Reed CR. The role of pharmacogenetics in treating central nervous system disorders. Exp Biol Med (Maywood) 2008; 233: 1504-1509.
11. Blanc O, Brousse G, Meary A, Leboyer M, Llorca PM. Pharmacogenetic of response efficacy to antipsychotics in schizophrenia: pharmacodynamic aspects. Review and implications for clinical research. Fundam Clin Pharmacol 2010; 24: 139-160.
12. Kinon BJ, Volavka J, Stauffer V, Edwards SE, Liu-Seifert H, Chen L et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol 2008; 28: 392-400.
13. Rorick-Kehn LM, Johnson BG, Burkey JL, Wright RA, Calligaro DO, Marek GJ et al. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)- 4-amino-2-sulfonylbicyclo[3.1.0]- hexane-4,6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther 2007; 321: 308-317. (Pubitemid 46456992)
14. Bymaster F, Perry KW, Nelson DL, Wong DT, Rasmussen K, Moore NA et al. Olanzapine: a basic science update. Br J Psychiatry Suppl 1999; 37: 36-40. (Pubitemid 29089310)
15. Muller DJ, Kennedy JL. Genetics of antipsychotic treatment emergent weight gain in schizophrenia. Pharmacogenomics 2006; 7: 863-887. (Pubitemid 44446736)
16. Mei L, Xiong WC. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci 2008; 9: 437-452. (Pubitemid 351704944)
17. Gupta M, Bhatnagar P, Grover S, Kaur H, Baghel R, Bhasin Y et al. Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics 2009; 10: 385-397.
18. Chen Q, He G, Chen Q, Wu S, Xu Y, Feng G et al. A case-control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese population. Schizophr Res 2005; 73: 21-26. (Pubitemid 39574674)
19. Egan MF, Straub RE, Goldberg TE, Yakub I, Callicott JH, Hariri AR et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci USA 2004; 101: 12604-12609. (Pubitemid 39122071)
20. Fujii Y, Shibata H, Kikuta R, Makino C, Tani A, Hirata N et al. Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatr Genet 2003; 13: 71-76. (Pubitemid 36724534)
21. Jurinke C, van den Boom D, Cantor CR, Koster H. Automated genotyping using the DNA MassArray technology. Methods Mol Biol 2001; 170: 103-116.
22. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995; 57: 289-300.
23. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265. (Pubitemid 40202029)
24. Peng G, Luo L, Siu H, Zhu Y, Hu P, Hong S et al. Gene and pathwaybased second wave analysis of genome-wide association studies. Eur J Hum Genet 2010; 18: 111-117.
25. Li D, Collier DA, He L. Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia. Hum Mol Genet 2006; 15: 1995-2002. (Pubitemid 43983273)
26. Wang F, Jiang T, Sun Z, Teng SL, Luo X, Zhu Z et al. Neuregulin 1 genetic variation and anterior cingulum integrity in patients with schizophrenia and healthy controls. J Psychiatry Neurosci 2009; 34: 181-186.
27. Cartmell J, Perry KW, Salhoff CR, Monn JA, Schoepp DD. The potent, selective mGlu2/3 receptor agonist LY379268 increases extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindole-3-acetic acid in the medial prefrontal cortex of the freely moving rat. J Neurochem 2000; 75: 1147-1154. (Pubitemid 30660504)
28. Rorick-Kehn LM, Johnson BG, Knitowski KM, Salhoff CR, Witkin JM, Perry KW et al. In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agoinst LY404039 in animal models of psychiatric disorders. Psychopharmacology (Berl) 2007; 193: 121-136. (Pubitemid 46906627)
29. Zhang Y, Bertolino A, Fazio L, Blasi G, Rampino A, Romano R et al. Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. Proc Natl Acad Sci USA 2007; 104: 20552-20557.
30. Bertolino A, Blasi G. The genetics of schizophrenia. Neuroscience 2009; 164: 288-299.
31. Centonze D, Grande C, Usiello A, Gubellini P, Erbs E, Martin AB et al. Receptor subtypes involved in the presynaptic and postsynaptic actions of dopamine on striatal interneurons. J Neurosci 2003; 23: 6245-6254. (Pubitemid 36875626)
32. Centonze D, Gubellini P, Usiello A, Rossi S, Tscherter A, Bracci E et al. Differential contribution of dopamine D2S and D2L receptors in the modulation of glutamate and GABA transmission in the striatum. Neuroscience 2004; 129: 157-166. (Pubitemid 39360951)
33. Marek GJ, Wright RA, Schoepp DD. 5-Hydroxytryptamine2A (5-HT2A) receptor regulation in rat prefrontal cortex: interaction of a phenethylamine hallucinogen and the metabotropic glutamate2/3 receptor agonist LY354740. Neurosci Lett 2006; 403: 256-260. (Pubitemid 44016015)
34. Gonzalez-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, Lopez-Gimenez JF et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 2008; 452: 93-97. (Pubitemid 351355090)
35. The ENCODE Project Consortium. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 2007; 447: 799-816.
36. Yelin R, Dahary D, Sorek R, Levanon EY, Goldstein O, Shoshan A et al. Widespread occurrence of antisense transcription in the human genome. Nat Biotechnol 2003; 21: 379-386. (Pubitemid 36397657)
37. Werner A, Sayer JA. Naturally occurring antisense RNA: function and mechanisms of action. Curr Opin Nephrol Hypertens 2009; 18: 343-349.
38. Patrick DL, Burns T, Morosini P, Rothman M, Gagnon DD, Wild D et al. Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia. Curr Med Res Opin 2009; 25: 325-338.